Premium
Ixekizumab: targeting plaque psoriasis and psoriatic arthritis
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1743
Subject(s) - ixekizumab , medicine , psoriatic arthritis , psoriasis , plaque psoriasis , dermatology , secukinumab , monoclonal antibody , arthritis , immunology , antibody
Ixekizumab (Taltz) is an anti‐interleukin‐17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom